Richard Davies
Keine laufenden Positionen mehr
Profil
Richard Davies served as Chairman at Capsant Neurotechnologies Ltd.
and Director at Southampton Asset Management Ltd.
He obtained an undergraduate degree from The University of Liverpool.
Ehemalige bekannte Positionen von Richard Davies
| Unternehmen | Position | Ende |
|---|---|---|
Southampton Asset Management Ltd.
 Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Chief Investment Officer | 08.01.2011 |
Capsant Neurotechnologies Ltd.
 Capsant Neurotechnologies Ltd. Pharmaceuticals: MajorHealth Technology Capsant Neurotechnologies Ltd. provided pre-clinical assay services to the drug development industry. It offered in-vitro tissue based screening technologies based on ex-vivo tissues and reaggregated 3D systems. The firm significantly reduced the costs associated with pre-clinical drug development and shortening the overall decision process in the selection of lead candidates for clinical evaluation. The company was founded by Lars Eric Sundstrom, Ashley Ker Pringle and John Edward Chad on June 21, 2002 and was headquartered in Gray's Inn, the United Kingdom. | Vorsitzender | - |
Ausbildung von Richard Davies
| The University of Liverpool | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Finance |
Capsant Neurotechnologies Ltd.
Capsant Neurotechnologies Ltd. Pharmaceuticals: MajorHealth Technology Capsant Neurotechnologies Ltd. provided pre-clinical assay services to the drug development industry. It offered in-vitro tissue based screening technologies based on ex-vivo tissues and reaggregated 3D systems. The firm significantly reduced the costs associated with pre-clinical drug development and shortening the overall decision process in the selection of lead candidates for clinical evaluation. The company was founded by Lars Eric Sundstrom, Ashley Ker Pringle and John Edward Chad on June 21, 2002 and was headquartered in Gray's Inn, the United Kingdom. | Health Technology |
